Home » Stocks » KURA

Kura Oncology, Inc. (KURA)

Stock Price: $34.09 USD -0.56 (-1.62%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $35.60 +1.51 (4.43%) Jan 15, 5:36 PM
Market Cap 2.25B
Revenue (ttm) n/a
Net Income (ttm) -81.33M
Shares Out 56.41M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $34.09
Previous Close $34.65
Change ($) -0.56
Change (%) -1.62%
Day's Open 34.35
Day's Range 33.25 - 34.61
Day's Volume 706,148
52-Week Range 6.45 - 41.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

– Panel discussion on precision medicine to be hosted by former FDA Commissioner Dr. Scott Gottlieb – – Panel discussion on precision medicine to be hosted by former FDA Commissioner Dr. Scott...

GlobeNewsWire - 1 week ago

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the tr...

GlobeNewsWire - 1 month ago

SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the tr...

Seeking Alpha - 1 month ago

Kura Oncology looks an attractive opportunity in the Precision Medicine / Targeted Therapies sector.

GlobeNewsWire - 1 month ago

SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the tr...

GlobeNewsWire - 1 month ago

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the tr...

GlobeNewsWire - 1 month ago

SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the tr...

GlobeNewsWire - 1 month ago

– Evidence of biologic activity observed in each dose-escalation cohort treated to date –

GlobeNewsWire - 1 month ago

Event to follow presentation of preliminary clinical data for menin inhibitor KO-539 at ASH Event to follow presentation of preliminary clinical data for menin inhibitor KO-539 at ASH

Seeking Alpha - 2 months ago

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the tr...

GlobeNewsWire - 2 months ago

SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment ...

GlobeNewsWire - 2 months ago

– Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of HNSCC –

GlobeNewsWire - 3 months ago

– First clinical data from the KOMET-001 study to be presented on December 5, 2020 – – First clinical data from the KOMET-001 study to be presented on December 5, 2020 –

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...

Investors Business Daily - 4 months ago

Kura Oncology shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. The post Kura Oncology Clears Key Benchmark, Hitting 90-Plus RS Rating appeared first on ...

Zacks Investment Research - 4 months ago

Kura Oncology (KURA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 4 months ago

SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatmen...

Seeking Alpha - 5 months ago

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the ...

GlobeNewsWire - 5 months ago

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatmen...

GlobeNewsWire - 7 months ago

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the ...

GlobeNewsWire - 8 months ago

– Oral presentation to highlight clinical data for tipifarnib in HRAS mutant solid tumors, including overall survival data in head and neck squamous cell carcinoma – – Oral presentation to hig...

GlobeNewsWire - 8 months ago

SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the t...

GlobeNewsWire - 8 months ago

SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the t...

GlobeNewsWire - 8 months ago

SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the t...

Seeking Alpha - 8 months ago

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2020 Results - Earnings Call Transcript

The Motley Fool - 8 months ago

Kura Oncology is riding the coattails of another clinical-stage biopharmaceutical company.

GlobeNewsWire - 10 months ago

– Second Fast Track designation for tipifarnib further highlights potential for tipifarnib to address unmet need for patients –

Seeking Alpha - 10 months ago

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success –

GlobeNewsWire - 1 year ago

Company strengthens leadership team to support pre-commercial efforts and launch optimization Company strengthens leadership team to support pre-commercial efforts and launch optimization

GlobeNewsWire - 1 year ago

– Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC –

GlobeNewsWire - 1 year ago

– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma –

Seeking Alpha - 1 year ago

Kura Oncology Should Be On Your Radar With Upcoming Presentation For Cancer Study

Seeking Alpha - 1 year ago

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

– Former Biogen senior counsel brings more than 20 years of combined in-house and law firm experience – – Former Biogen senior counsel brings more than 20 years of combined in-house and law fi...

GlobeNewsWire - 1 year ago

– 56% confirmed ORR in 18 efficacy-evaluable HNSCC patients with HRAS mutant variant allele frequency ≥ 20% –

GlobeNewsWire - 1 year ago

– Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29th –

GlobeNewsWire - 1 year ago

SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatmen...

GlobeNewsWire - 1 year ago

– Accomplished executive adds extensive experience in launching novel therapies as Company sets sights on commercial readiness – – Accomplished executive adds extensive experience in launching...

GlobeNewsWire - 1 year ago

– KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction –

GlobeNewsWire - 1 year ago

– Confirmed objective responses achieved in five of 13 evaluable patients –

Seeking Alpha - 1 year ago

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Kura Oncology, Inc. (KURA).

Seeking Alpha - 1 year ago

Today, we revisit Kura Oncology which recently disclosed encouraging mid-stage trial results around its primary drug candidate.

Market Watch - 1 year ago

Shares of Kura Oncology Inc. soared 27% toward a record high in premarket trading Friday, after the biopharmaceutical company announced a phase 2 trial of its lymphoma treatment achieved its p...

Seeking Alpha - 1 year ago

Kura Oncology's (KURA) CEO Troy Wilson on Q1 2019 Results - Earnings Call Transcript

About KURA

Kura Oncology, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment ... [Read more...]

Industry
Biotechnology
Founded
2014
CEO
Troy Wilson
Employees
83
Stock Exchange
NASDAQ
Ticker Symbol
KURA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for Kura Oncology stock is "Buy." The 12-month stock price forecast is 45.00, which is an increase of 32.00% from the latest price.

Price Target
$45.00
(32.00% upside)
Analyst Consensus: Buy